L'inibizione delle metalloproteasi: Applicazioni terapeutiche nelle patologie reumatiche

Clinica Terapeutica

Volumn 150, Issue 4, 1999, Pages 295-299

  Barracchini, A ^a   Franceschini, N ^a   Di Giulio, A ^a   Amicosante, G ^a   Oratore, A ^a   Minisola, G ^a   Pantaleoni, Gian Carlo ^a,b  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Collagenase; Matrix metalloproteases; Rifamycins

Indexed keywords

BATIMASTAT; BB 1101; BB 1433; BE 166227B; COLLAGENASE; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; N1 [2,2 DIMETHYL 1 [(METHYLAMINO)CARBONYL]PROPYL] N4 HYDROXY 2 (2 METHYLPROPYL)BUTANEDIAMIDE; RIFAMYCIN DERIVATIVE; RO 319790; RO 32 3552; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; DRUG EFFICACY; ENZYME INHIBITOR INTERACTION; EXTRACELLULAR MATRIX; HUMAN; ORAL DRUG ADMINISTRATION; OSTEOARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS;

ARTHRITIS, RHEUMATOID; COLLAGENASES; HUMANS; MATRIX METALLOPROTEINASES; OSTEOARTHRITIS; RIFAMYCINS; THYMIDINE MONOPHOSPHATE;

EID: 0032758903     PISSN: 00099074     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Dean DD: Proteinase-mediate cartilage degradation in osteoarthritis. Semin Arthritis Rheum 20: 2-11, 1991 (suppl. 2)
2. Breedveld FC, Labefer GJM, Siegert CEH, et al.: Elastase and collagenase activities in synovial fluid of patients with arthritis. J Rheumatol 14: 1008-1012, 1987
3. Woessner JJr.: The family of metalloproteinases. Ann N Y Acad Sci 732: 11-21, 1994
4. Emonard H, Grimaud JA: Matrix Metalloproteinases. A review. Cell Mol Biol 36: 131-153, 1990
5. Yong VW, Krekoski CA, Forsyth PA, et al.: Matrix metalloproteinases and diseases of the CNS. T I N S 21: 75-80, 1998
6. Nagase H: Activation mechanism of matrix metalloproteinase. Biol Chem 378: 151-160, 1997
7. Martel-Pelletier J, McCollum R, Fujimoto N, et al.: Excess of metalloproteases over tissue inhibitor of metalloproteases may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis. Lab Invest 70: 807-815, 1994
8. Dean DD, Martel-Pelletier J, Pelletier JP, et al.: Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J Clin Invest 84: 678-685, 1989
9. Pelletier JP, Mineau F, Faure MP, et al.: Inbalance between the mechanism of activation and inhibition of metalloproteases in the early lesions of experimental osteoarthritis. Arthritis Rheum 33: 1466-1476, 1990
10. Murphy G, Hembry R: Proteinases in rheumatoid arthritis. J Rheumatol 19: 61-64, 1992 (suppl 32)
11. Lohmander HS, Lori AH, Lark MW: Metalloproteinase, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis. Arthritis Rheum 36: 181-189, 1993
12. Larbre JP, Moore AR, Da Silva JAP, et al.: Direct degradation of articular cartilage by rheumatoid synovial fluid: contribution of proteolytic enzymes. J Rheumatol. 21: 1796-1801, 1994
13. Beckett, RP, Davidson, AH, Drummond, et al.: Recent advances in matrix metalloproteinase inhibitor research. Drug Disc Today 1: 16-26, 1996
14. Cawston T: Matrix metalloproteinase and TIMPs: properties and implications for the rheumatic diseases. Mol. Med. Today 4: 130-137, 1998
15. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ: Matrix metalloproteinase inhibitors. Invest New Drugs 15: 61-75, 1997
16. Lewis EJ, Bishop J, Bottomley K, et al.: efficacy of Ro 31-9790, an orally active collagenase inhibitor, in animal models of arthritis. Rev Exp Rheumatol 20: 494-496, 1993 (suppl. 1)
17. Tamura Y, Watanabe F, Nakatani T, et al.: Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-SulphonylaminoAcid Derivatives. J Med Chem 41: 640-649, 1998
18. Di Martino M, Wolff C, Stroup G, et al.: Anti-arthritic activity of hydroxamic acid-based pseudopeptide inhibitors of matrix metalloproteinases and TNF alpha processing, Inflamm Res 46: 211-215, 1997
19. Lewis EJ, Bishap KMK, Bottomley D, et al.: Ro 32-3555, an orally active collagenase inhibitor prevents cartilage breakdown in vitro and in vivo. Br J Pharmacol 121: 540-546, 1997
20. Vincenti MP, Clark IM, Brinckerhoff CE: Using inhibitors of metallo-proteinases to treat arthritis. Arthritis Rheum 37: 1115-1126, 1994
21. Cawston, TE: Metalloproteinase inhibitors and the prevention of connective tissue breakdown. Pharmacol Ther 70, 163-182, 1996
22. Caruso I, Principi N, D'Urbino G, et al.: Rifamycin SV administered by intra-articular infiltrations shows disease modifying activity in patients with pauci or polyarticular juvenile rheumatoid arthritis. J Int Med Res 21: 243-256, 1993
23. Borg AA, Davis MJ, Fowler PD, et al: Rifampicin in early rheumatoid arthritis. Scand J Rheumatol 22: 39-42, 1993
24. Di Giulio A, Barracchini A, Cellai L, et al.:Rifamycins as inhibitors of collagenase activity: their possible pharmacological role in collagen degradative diseases. Int J Pharm 144: 27-35, 1996